Skip to main content

Advertisement

Table 1 Patient and specimen characteristics

From: Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

Characteristics No. %
Sex   
  Male 67 59.3
  Female 46 40.7
Melanoma type   
  Primary 41 36.3
  Metastatic: 72 63.7
   Node 24 33.3
   Skin 23 31.9
   Brain 7 9.7
   Lung 5 6.9
   Eye 4 5.6
   Liver 3 4.2
   Others (intestine, bone, etc.) 6 8.3
Average age (years) 63.2  
Sample type   
  Slide 36 31.9
   Tissue surface mean (mm2) 97.2  
   [DNA] (ng/μl) 38.7  
  Punch 77 68.1
   Tissue volume mean (mm3) 1.02  
   [DNA] (ng/μl) 266  
Tumor cell content 1   
  <80% 12 10.6
  >80% 101 89.4
Melanin rate   
  Sample 0 105 92.9
  Sample + (5 to 15%) 5 4.4
  Sample ++ (20 to 45%) 2 1.8
  Sample +++ (>50%) 1 0.9
Necrosis rate   
  Sample 0 92 81.4
  Sample + (<10%) 15 13.3
  Sample ++ to +++ (>10%) 6 5.3
  1. 1After macro-dissection, when applicable.